UPM, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with Amerigen Pharmaceuticals, Inc. to commercially manufacture two ANDA products for a 10 year supply term. In addition, the agreement allows for UPM to develop and potentially commercially supply several additional ANDA products for Amerigen over the next few years. UPM acquired the 475,000 square foot Pfizer manufacturing facility in Bristol, Tennessee in July of 2013 and, eventually, all of these products will be made at this new facility.
Dr. John M. Gregory, Chairman and CEO of Gregory Pharmaceutical Holdings, Inc., said, "UPM has been working with Amerigen for the past three years providing development services for their significant pipeline of ANDA products. We have a strong working relationship with their company and are impressed with their technical team and their business development approach. We believe this agreement cements our partnership with Amerigen. Also, it is another example of UPM's transition from a company that formerly focused on only early stage development, but now, provides a full range of solid dose commercial services for our clients."
Jonathan Embleton, Chief Business Officer of Amerigen, said, "Amerigen looks forward to a long relationship with UPM. We are excited about our upcoming product portfolio and the role UPM will play in providing products to market."
Amerigen is a privately held company founded in 2007 and is located in central New Jersey and has additional manufacturing facilities in China. Their focus is the development, manufacture and sale of high quality generic pharmaceutical products for the United States and China.